BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 34944094)

  • 1. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
    Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
    Lønning PE; Nikolaienko O; Pan K; Kurian AW; Eikesdal HP; Pettinger M; Anderson GL; Prentice RL; Chlebowski RT; Knappskog S
    JAMA Oncol; 2022 Nov; 8(11):1579-1587. PubMed ID: 36074460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
    Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
    Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
    Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer.
    El-Arabey AA; Abdalla M
    Hum Cell; 2022 Jul; 35(4):1298-1300. PubMed ID: 35459984
    [No Abstract]   [Full Text] [Related]  

  • 7. Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.
    Eismann J; Heng YJ; Waldschmidt JM; Vlachos IS; Gray KP; Matulonis UA; Konstantinopoulos PA; Murphy CJ; Nabavi S; Wulf GM
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):503-514. PubMed ID: 31745703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Wallbillich JJ; Morris RT; Ali-Fehmi R
    Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
    Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
    Mittempergher L
    Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
    Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
    Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
    J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
    Mittempergher L; Piskorz AM; Bosma AJ; Michaut M; Wisman GBA; Kluin RJC; Nieuwland M; Brugman W; van der Ven KJW; Marass F; Morris J; Rosenfeld N; Jimenez-Linan M; de Jong S; van der Zee AGJ; Brenton JD; Bernards R
    PLoS One; 2020; 15(7):e0235766. PubMed ID: 32639993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutional
    Al-Moghrabi N; Al-Showimi M; Alqahtani A; Almalik O; Alhusaini H; Almalki G; Saad A; Alsunayi E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.